Subhash Tripathi, PhD, on Developing Safe, Specific Engineered Treg Cell Therapy


The senior researcher at Seattle Children’s discussed advantages of engineered Tregs compared with natural Tregs.

“There are disadvantages associated with current adaptive cell therapies, which are based on natural regulatory T-cells. To cite some of those key technical hurdles, there is a huge rarity of these populations in vivo. So if you get them, you have to scale up for manufacturing, which is very difficult, and then they are very unstable and have plasticity. They have a very poor engraftment in vivo. And sometimes, if you get these cells from patients, they might be defective.”

CAR-CISC EngTreg cells may have therapeutic potential in transplantation, autoimmune and/or autoinflammatory disease, including diabetes type 1 and multiple sclerosis, among others. The lab of David Rawlings, MD, at Seattle Children’s Hospital, has been working on developing and improving regulatory T-cell (Treg) therapies for these uses. A member of the Rawlings lab, Subhash Tripathi, PhD, senior researcher at Seattle Children’s, presented findings from the development and validation of Treg therapies, the final iteration of which was an A2-CAR-CISC EngTreg cell, at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting, held May 7 to 10, 2024, in Baltimore, Maryland.

A2-CAR-CISC EngTreg cells use dual homology-directed-repair gene editing to generate HLA-A*02 antibody-based chimeric antigen receptor (CAR) Treg cells. Early mice studies demonstrate specific targeting and no cases of graft versus host disease. CGTLive spoke to Tripathi to learn more about the research he has done at the Rawlings lab with Treg cells. He gave an overview of the development of engineered Treg cells and their advantages over natural Treg cells.

Tripathi SK, Dahl NP, Grimm A, et al. HLA-A2 CAR/IL-2-CISC Engineered Treg Exhibit Robust In Vitro and In Vivo Efficacy. Presented at: ASGCT 27th Annual Meeting, May 7-10; Baltimore, Maryland. Abstract #90
Related Videos
Luke Roberts, MBBS, PhD, on Challenges in Developing Gene Therapy for Heart Failure
Steve Kanner, PhD, the chief scientific officer of Caribou Biosciences
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Lisa Nieland on Slowing Tumor Growth in Glioblastoma With Novel AAV Therapy
Manali Kamdar, MD, on Acclimating to Routine CAR T Practice in the Field
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Jennifer Taylor-Cousar, MD, MSCS, on Early Signals of Efficacy With Cystic Fibrosis Gene Therapy
Leigh Ramos-Platt, MD, on Looking Forward to Gene Therapy’s Growth
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Manali Kamdar, MD, on Evaluating Liso-Cel in Mantle Cell Lymphoma by Lines of Therapy, Prior BTKi
© 2024 MJH Life Sciences

All rights reserved.